After neoadjuvant chemoradiotherapy, the expression level of IGHG2 increased significantly in rectal cancer, indicating that IGHG2 was originally with a low expression in tumor cells and existed as a protective factor, which was consistent with our prognostic analysis. Here, IGHG2 is linked to rectal cancer.